Global Biosimilar Insulin Market Research Report 2020

Table of Contents

1 Biosimilar Insulin Market Overview

• 1.1 Product Overview and Scope of Biosimilar Insulin
• 1.2 Biosimilar Insulin Segment by Type
  • 1.2.1 Global Biosimilar Insulin Sales Growth Rate Comparison by Type (2021-2026)
  • 1.2.2 Rapid Acting Insulins
  • 1.2.3 Short Acting Insulins
  • 1.2.4 Intermediate Insulins
  • 1.2.5 Long Lasting Insulins
• 1.3 Biosimilar Insulin Segment by Application
  • 1.3.1 Biosimilar Insulin Sales Comparison by Application: 2020 VS 2026
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Medical Center
• 1.4 Global Biosimilar Insulin Market Size Estimates and Forecasts
  • 1.4.1 Global Biosimilar Insulin Revenue 2015-2026
  • 1.4.2 Global Biosimilar Insulin Sales 2015-2026
  • 1.4.3 Biosimilar Insulin Market Size by Region: 2020 Versus 2026

2 Global Biosimilar Insulin Market Competition by Manufacturers

• 2.1 Global Biosimilar Insulin Sales Market Share by Manufacturers (2015-2020)
• 2.2 Global Biosimilar Insulin Revenue Share by Manufacturers (2015-2020)
• 2.3 Global Biosimilar Insulin Average Price by Manufacturers (2015-2020)
• 2.4 Manufacturers Biosimilar Insulin Manufacturing Sites, Area Served, Product Type
• 2.5 Biosimilar Insulin Market Competitive Situation and Trends
  • 2.5.1 Biosimilar Insulin Market Concentration Rate
  • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
  • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
• 2.7 Primary Interviews with Key Biosimilar Insulin Players (Opinion Leaders)

3 Biosimilar Insulin Retrospective Market Scenario by Region

• 3.1 Global Biosimilar Insulin Retrospective Market Scenario in Sales by Region: 2015-2020
• 3.2 Global Biosimilar Insulin Retrospective Market Scenario in Revenue by Region: 2015-2020
• 3.3 North America Biosimilar Insulin Market Facts & Figures by Country
  • 3.3.1 North America Biosimilar Insulin Sales by Country
  • 3.3.2 North America Biosimilar Insulin Sales by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Biosimilar Insulin Market Facts & Figures by Country
  • 3.4.1 Europe Biosimilar Insulin Sales by Country
  • 3.4.2 Europe Biosimilar Insulin Sales by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Biosimilar Insulin Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Biosimilar Insulin Sales by Region
  • 3.5.2 Asia Pacific Biosimilar Insulin Sales by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Biosimilar Insulin Market Facts & Figures by Country
  • 3.6.1 Latin America Biosimilar Insulin Sales by Country
  • 3.6.2 Latin America Biosimilar Insulin Sales by Country
  • 3.6.3 Mexico
  • 3.6.3 Brazil
  • 3.6.3 Argentina
• 3.7 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Biosimilar Insulin Sales by Country
  • 3.7.2 Middle East and Africa Biosimilar Insulin Sales by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Biosimilar Insulin Historic Market Analysis by Type

• 4.1 Global Biosimilar Insulin Sales Market Share by Type (2015-2020)
• 4.2 Global Biosimilar Insulin Revenue Market Share by Type (2015-2020)
• 4.3 Global Biosimilar Insulin Price Market Share by Type (2015-2020)
• 4.4 Global Biosimilar Insulin Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Biosimilar Insulin Historic Market Analysis by Application

• 5.1 Global Biosimilar Insulin Sales Market Share by Application (2015-2020)
• 5.2 Global Biosimilar Insulin Revenue Market Share by Application (2015-2020)
• 5.3 Global Biosimilar Insulin Price by Application (2015-2020)

6 Company Profiles and Key Figures in Biosimilar Insulin Business

• 6.1 Pfizer
  • 6.1.1 Corporation Information
  • 6.1.2 Pfizer Description, Business Overview and Total Revenue
  • 6.1.3 Pfizer Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.1.4 Pfizer Products Offered
  • 6.1.5 Pfizer Recent Development
• 6.2 Biogenomics
  • 6.2.1 Biogenomics Biosimilar Insulin Production Sites and Area Served
  • 6.2.2 Biogenomics Description, Business Overview and Total Revenue
  • 6.2.3 Biogenomics Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.2.4 Biogenomics Products Offered
  • 6.2.5 Biogenomics Recent Development
• 6.3 Eli Lilly
  • 6.3.1 Eli Lilly Biosimilar Insulin Production Sites and Area Served
  • 6.3.2 Eli Lilly Description, Business Overview and Total Revenue
  • 6.3.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.3.4 Eli Lilly Products Offered
  • 6.3.5 Eli Lilly Recent Development
• 6.4 Gan&Lee Pharmaceuticals
  • 6.4.1 Gan&Lee Pharmaceuticals Biosimilar Insulin Production Sites and Area Served
  • 6.4.2 Gan&Lee Pharmaceuticals Description, Business Overview and Total Revenue
  • 6.4.3 Gan&Lee Pharmaceuticals Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.4.4 Gan&Lee Pharmaceuticals Products Offered
  • 6.4.5 Gan&Lee Pharmaceuticals Recent Development
• 6.5 Geropharm
  • 6.5.1 Geropharm Biosimilar Insulin Production Sites and Area Served
  • 6.5.2 Geropharm Description, Business Overview and Total Revenue
  • 6.5.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.5.4 Geropharm Products Offered
  • 6.5.5 Geropharm Recent Development
• 6.6 Julphar Gulf Pharmaceutical Industries
  • 6.6.1 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Production Sites and Area Served
  • 6.6.2 Julphar Gulf Pharmaceutical Industries Description, Business Overview and Total Revenue
  • 6.6.3 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.6.4 Julphar Gulf Pharmaceutical Industries Products Offered
  • 6.6.5 Julphar Gulf Pharmaceutical Industries Recent Development
• 6.7 Paras Biopharmaceuticals
  • 6.6.1 Paras Biopharmaceuticals Biosimilar Insulin Production Sites and Area Served
  • 6.6.2 Paras Biopharmaceuticals Description, Business Overview and Total Revenue
  • 6.6.3 Paras Biopharmaceuticals Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.4.4 Paras Biopharmaceuticals Products Offered
  • 6.7.5 Paras Biopharmaceuticals Recent Development
• 6.8 Samsung Bioepis
  • 6.8.1 Samsung Bioepis Biosimilar Insulin Production Sites and Area Served
  • 6.8.2 Samsung Bioepis Description, Business Overview and Total Revenue
  • 6.8.3 Samsung Bioepis Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.8.4 Samsung Bioepis Products Offered
  • 6.8.5 Samsung Bioepis Recent Development
• 6.9 Sedico
  • 6.9.1 Sedico Biosimilar Insulin Production Sites and Area Served
  • 6.9.2 Sedico Description, Business Overview and Total Revenue
  • 6.9.3 Sedico Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.9.4 Sedico Products Offered
  • 6.9.5 Sedico Recent Development
• 6.10 Wockhardt
  • 6.10.1 Wockhardt Biosimilar Insulin Production Sites and Area Served
  • 6.10.2 Wockhardt Description, Business Overview and Total Revenue
  • 6.10.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.10.4 Wockhardt Products Offered
  • 6.10.5 Wockhardt Recent Development
• 6.11 Teva Pharmaceuticals
  • 6.11.1 Teva Pharmaceuticals Biosimilar Insulin Production Sites and Area Served
  • 6.11.2 Teva Pharmaceuticals Biosimilar Insulin Description, Business Overview and Total Revenue
  • 6.11.3 Teva Pharmaceuticals Biosimilar Insulin Sales, Revenue and Gross Margin (2015-2020)
  • 6.11.4 Teva Pharmaceuticals Products Offered
  • 6.11.5 Teva Pharmaceuticals Recent Development

7 Biosimilar Insulin Manufacturing Cost Analysis

• 7.1 Biosimilar Insulin Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Raw Materials Price Trend
  • 7.1.3 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Biosimilar Insulin
• 7.4 Biosimilar Insulin Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Biosimilar Insulin Distributors List
• 8.3 Biosimilar Insulin Customers

9 Market Dynamics

• 9.1 Market Trends
• 9.2 Opportunities and Drivers
• 9.3 Challenges
• 9.4 Porter's Five Forces Analysis

10 Global Market Forecast

• 10.1 Global Biosimilar Insulin Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Biosimilar Insulin by Type (2021-2026)
  • 10.1.2 Global Forecasted Revenue of Biosimilar Insulin by Type (2021-2026)
• 10.2 Biosimilar Insulin Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Biosimilar Insulin by Application (2021-2026)
  • 10.2.2 Global Forecasted Revenue of Biosimilar Insulin by Application (2021-2026)
• 10.3 Biosimilar Insulin Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Biosimilar Insulin by Region (2021-2026)
  • 10.3.2 Global Forecasted Revenue of Biosimilar Insulin by Region (2021-2026)
• 10.4 North America Biosimilar Insulin Estimates and Projections (2021-2026)
• 10.5 Europe Biosimilar Insulin Estimates and Projections (2021-2026)
• 10.6 Asia Pacific Biosimilar Insulin Estimates and Projections (2021-2026)
• 10.7 Latin America Biosimilar Insulin Estimates and Projections (2021-2026)
• 10.8 Middle East and Africa Biosimilar Insulin Estimates and Projections (2021-2026)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List